Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.34 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | YWHAZ | P63104 | 3/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25510322 | 0.89 | CA2 (0.35) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL25509870 | 0.89 | CA2 (0.35) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL13139549 | 0.88 | CA2 (0.38) | CA2CA1CA9 | |
| SCHEMBL27594926 | 0.80 | CA2 (0.36) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL9812954 | 0.80 | CA2 (0.36) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL7151445 | 0.79 | CA2 (0.35) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL28066823 | 0.79 | CA2 (0.35) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL1151202 | 0.79 | CA2 (0.35) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL10419819 | 0.79 | CA2 (0.35) | CA2CA1CA9YWHAZMGAM | |
| SCHEMBL13129796 | 0.77 | KMT2A (0.37) | CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | INSTITUT PASTEUR (FR) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239584-A1 | GLYCOCONJUGATES AND USE THEREOF AS VACCINE AGAINST SHIGELLA FLEXNERI SEROTYPE 3A AND X | ST3GAL3, SI, STT3A | CA2 3218/4885CA1 1299/4885CA9 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.